# Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients

Source: https://onco.cc/trials/nct00493181/  
OnCo record `nct00493181` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Oprelvekin in Leukaemia and Chronic myeloid leukaemia, run by M.D. Anderson Cancer Center, completed.

## Summary

Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients is a phase 2 interventional study registered as NCT00493181 by M.D. Anderson Cancer Center, with 8 participants recorded, started 2005-10 and reaching its primary completion in 2011-01. Interventions recorded: Interleukin-11 (IL-11 or Neumega). Conditions recorded: Leukemia, Chronic Myelogenous Leukemia, Chronic Myeloid Leukemia.

Linked to the drug Oprelvekin because the registry names it among its interventions and Leukaemia and Chronic myeloid leukaemia among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00493181
- Phase: 2
- Setting: The Effect of Interleukin 11 on Thrombocytopenia Associated With Imatinib or Other Tyrosine Kinase Inhibitor Therapy in Patients With Chronic Myelogenous Leukemia
- Sponsor: M.D. Anderson Cancer Center
- Enrolled: 8

## Sources

- ClinicalTrials.gov NCT00493181: https://clinicaltrials.gov/study/NCT00493181

## Connected records

- cancers: [Chronic myeloid leukaemia (CML)](https://onco.cc/cancers/cml/), [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/)
- drugs: [Oprelvekin](https://onco.cc/drugs/oprelvekin/)

---
JSON: https://onco.cc/api/v1/entities/nct00493181.json